DOCK4 and breast carcinoma: The mechanism of action of zoledronate on nonbone metastases is currently unknown; however, it has been previously described that zoledronic acid can inhibit the proliferation, survival, and migration of breast cancer cells.13 DOCK4 levels may therefore have prognostic potential for nonskeletal as well as skeletal metastases.